Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) EBITDA Margin (2022 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed EBITDA Margin for 4 consecutive years, with 146.66% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 20419.0% to 146.66% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 203.37% through Dec 2025, down 21253.0% year-over-year, with the annual reading at 203.37% for FY2025, 21253.0% down from the prior year.
  • EBITDA Margin hit 146.66% in Q4 2025 for ARS Pharmaceuticals, up from 157.26% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 57.54% in Q4 2024 to a low of 176180.0% in Q2 2023.
  • Historically, EBITDA Margin has averaged 21917.45% across 4 years, with a median of 997.53% in 2022.
  • Biggest five-year swings in EBITDA Margin: tumbled -17479638bps in 2023 and later surged 17367260bps in 2024.
  • Year by year, EBITDA Margin stood at 3483.07% in 2022, then plummeted by -4958bps to 176180.0% in 2023, then surged by 100bps to 57.54% in 2024, then tumbled by -355bps to 146.66% in 2025.
  • Business Quant data shows EBITDA Margin for SPRY at 146.66% in Q4 2025, 157.26% in Q3 2025, and 286.32% in Q2 2025.